# Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

> **NCT05721651** · PHASE2 · UNKNOWN · sponsor: **Wu Jun** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Fruquintinib+PD-1

## Key facts

- **NCT ID:** NCT05721651
- **Lead sponsor:** Wu Jun
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04
- **Primary completion:** 2025-03
- **Final completion:** 2026-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05721651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05721651, "Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05721651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*